M. Wirden

发表

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.

V. Calvez, C. Katlama, O. Delelis, 2009, The Journal of antimicrobial chemotherapy.

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2011, The Journal of antimicrobial chemotherapy.

Caution is needed in interpreting HIV transmission chains by ultradeep sequencing

V. Calvez, C. Katlama, F. Barin, 2019, AIDS.

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels

V. Calvez, C. Katlama, A. Boyd, 2019, Open forum infectious diseases.

Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.

V. Calvez, R. Tubiana, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

V. Calvez, C. Charpentier, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

Comparative Performances of HIV-1 RNA Load Assays at Low Viral Load Levels: Results of an International Collaboration

M. Poljak, A. Wensing, P. Harrigan, 2013, Journal of Clinical Microbiology.

Dual Raltegravir/Etravirine Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy

R. Tubiana, C. Katlama, L. Schneider, 2012, Antiviral therapy.

Medical features of COVID-19 and influenza infection: A comparative study in Paris, France

V. Calvez, D. Boutolleau, S. Burrel, 2020, Journal of Infection.

Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients

V. Calvez, C. Katlama, B. Roquebert, 2006, Antimicrobial Agents and Chemotherapy.

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing

V. Calvez, C. Charpentier, C. Katlama, 2018, The Journal of antimicrobial chemotherapy.

HIV-1 diagnosis with unquantifiable viraemia: don’t be naive, look for antiretroviral drugs

V. Calvez, C. Charpentier, R. Tubiana, 2017, Journal of Antimicrobial Chemotherapy.

No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Upgraded Cobas Ampliprep-Cobas TaqMan Version 2.0 HIV-1 RNA Quantification Assay versus First Version: Correction of Underestimations

V. Calvez, R. Tubiana, C. Katlama, 2011, Journal of Clinical Microbiology.

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.

V. Calvez, C. Katlama, M. Valantin, 2011, The Journal of antimicrobial chemotherapy.

Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score

V. Calvez, R. Tubiana, C. Katlama, 2014, Infection.

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

V. Calvez, C. Charpentier, S. Burrel, 2021, Journal of Infection.

Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtype.

V. Calvez, C. Katlama, P. Girard, 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.

V. Calvez, F. Ceccherini‐Silberstein, C. Katlama, 2011, The Journal of antimicrobial chemotherapy.

MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study

V. Calvez, R. Tubiana, C. Katlama, 2004, AIDS.

Resistance mutations before and after tenofovir regimen failure in HIV‐1 infected patients

V. Calvez, R. Tubiana, C. Katlama, 2005, Journal of medical virology.

Disparities in HIV‐1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations

V. Calvez, C. Charpentier, C. Katlama, 2017, HIV medicine.

Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.

V. Calvez, C. Katlama, P. Girard, 2015, The Journal of antimicrobial chemotherapy.

Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.

V. Calvez, R. Tubiana, C. Katlama, 2009, The Journal of antimicrobial chemotherapy.

Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors.

V. Calvez, C. Charpentier, D. Descamps, 2013, The Journal of antimicrobial chemotherapy.

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

Luba Tchertanov, Vincent Calvez, Christine Katlama, 2008, Antimicrobial Agents and Chemotherapy.

Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIs

V. Calvez, R. Tubiana, C. Delaugerre, 2003, Journal of Clinical Microbiology.

Foscarnet Salvage Therapy for Patients with Late-Stage HIV Disease and Multiple Drug Resistance

V. Calvez, C. Katlama, E. Caumes, 2005, Antiviral therapy.

Pharmacokinetics, protein‐binding‐adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment‐naïve HIV‐infected patients *

V. Calvez, C. Katlama, G. Peytavin, 2010, HIV medicine.

Clinical Validation of Saquinavir/Ritonavir Genotypic Resistance Score in Protease-Inhibitor-Experienced Patients

V. Calvez, C. Katlama, V. Soriano, 2007, Antiviral therapy.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

C. Rouzioux, P. Frange, Laurent Tran, 2015, The Journal of antimicrobial chemotherapy.

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution

V. Calvez, C. Katlama, B. Roquebert, 2005, AIDS.

Relationship between mutations in HIV‐1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre‐treated HIV infected patients

V. Calvez, C. Katlama, J. Deval, 2007, Journal of medical virology.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

V. Calvez, C. Charpentier, C. Delaugerre, 2017, The Journal of antimicrobial chemotherapy.

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.

V. Calvez, C. Katlama, O. Delelis, 2015, The Journal of antimicrobial chemotherapy.

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV‐1 reverse transcriptase (M184L and M184T)

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2018, Chemical biology & drug design.

Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network

F. Brun-Vézinet, B. Masquelier, C. Rouzioux, 2007, Antiviral therapy.

Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors

V. Calvez, R. Tubiana, C. Katlama, 2006, AIDS.

No HIV-1 molecular evolution on long term antiretroviral therapy initiated during primary HIV-1 infection.

V. Calvez, R. Tubiana, C. Katlama, 2020, AIDS.

Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure.

G. Carcelain, R. Tubiana, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

Evolution of viral quasispecies during SARS-CoV-2 infection

V. Calvez, D. Boutolleau, S. Burrel, 2020, Clinical Microbiology and Infection.

Detection of numerous HIV-1/MO recombinants in France

V. Lemée, M. Chaix, E. Gault, 2018, AIDS.

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2013, The Journal of antimicrobial chemotherapy.

French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002

F. Brun-Vézinet, P. André, B. Masquelier, 2005, Journal of acquired immune deficiency syndromes.

Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients

V. Calvez, C. Katlama, L. Schneider, 2003, AIDS.

Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996–2006 in France

C. Delaugerre, B. Masquelier, C. Rouzioux, 2009, AIDS.

Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes

V. Calvez, C. Katlama, B. Masquelier, 2009, Antimicrobial Agents and Chemotherapy.

Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

V. Calvez, C. Delaugerre, C. Katlama, 2003, Antimicrobial Agents and Chemotherapy.

Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in France

C. Charpentier, C. Delaugerre, Felix Feyertag, 2013, AIDS.

Highly multidrug-resistant HIV: clonal analysis and therapeutic strategies.

V. Calvez, R. Tubiana, C. Katlama, 2013, The Journal of antimicrobial chemotherapy.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.

V. Calvez, C. Katlama, S. Benichou, 2012, Antiviral research.

V. Calvez, C. Katlama, B. Masquelier, 2012, PloS one.

Role of HIV-1 DNA levels as clinical marker of HIV-1-associated nephropathies.

P. Cluzel, D. Sène, G. Lucas, 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

J. Avouac, P. Grimbert, P. Rémy, 2008, Kidney international.

Viral load and HIV-associated nephropathy.

H. Izzedine, V. Launay-Vacher, M. Wirden, 2005, The New England journal of medicine.

Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission.

R. Tubiana, C. Katlama, A. Gautheret-Dejean, 2002, AIDS.

Clinically Relevant Genotype Interpretation of Resistance to Didanosine

V. Calvez, J. Molina, P. Flandre, 2005, Antimicrobial Agents and Chemotherapy.

Genotypic Determinants of the Virological Response to Tenofovir Disoproxil Fumarate in Nucleoside Reverse Transcriptase Inhibitor-Experienced Patients

F. Brun-Vézinet, B. Masquelier, D. Costagliola, 2003, Antiviral therapy.

Efficacy and safety of tenofovir double‐dose in treatment‐experienced HIV‐infected patients: The tenoplus study

V. Calvez, C. Katlama, G. Peytavin, 2007, Journal of medical virology.

Positive Impact of HIV-1 gag Cleavage Site Mutations on the Virological Response to Darunavir Boosted with Ritonavir

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2011, Antimicrobial Agents and Chemotherapy.

Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients

V. Calvez, C. Katlama, A. Marcelin, 2007, AIDS.

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.

V. Calvez, C. Katlama, D. Costagliola, 2007, The Journal of infection.

Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.

V. Calvez, R. Tubiana, C. Katlama, 2020, The Journal of antimicrobial chemotherapy.

Multicenter comparison of the Cobas 6800 system with the RealStar RT-PCR kit for the detection of SARS-CoV-2

C. Delaugerre, D. Boutolleau, D. Descamps, 2020, bioRxiv.

New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.

V. Calvez, C. Charpentier, C. Katlama, 2019, The Journal of antimicrobial chemotherapy.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.

C. Delaugerre, S. Yerly, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients

Vincent Calvez, Christine Katlama, V. Calvez, 2005, AIDS.

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.

V. Calvez, C. Katlama, F. Raffi, 2016, The Journal of antimicrobial chemotherapy.

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.

V. Calvez, C. Charpentier, B. Masquelier, 2014, The Journal of antimicrobial chemotherapy.

Impact of Discrepancies between the Abbott RealTime and Cobas TaqMan Assays for Quantification of Human Immunodeficiency Virus Type 1 Group M Non-B Subtypes

V. Calvez, R. Tubiana, C. Katlama, 2009, Journal of Clinical Microbiology.

Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals

C. Charpentier, C. Delaugerre, J. Pawlotsky, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure

V. Calvez, C. Katlama, S. Fourati, 2012, AIDS.

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)

V. Calvez, C. Charpentier, C. Delaugerre, 2018, The Journal of antimicrobial chemotherapy.

Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy

V. Calvez, C. Delaugerre, C. Katlama, 2004, Antimicrobial Agents and Chemotherapy.

Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of infectious diseases.

Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study.

R. Tubiana, C. Katlama, G. Peytavin, 2019, The Journal of antimicrobial chemotherapy.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.

V. Calvez, C. Charpentier, M. Lê, 2020, The Journal of antimicrobial chemotherapy.

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.

V. Calvez, C. Charpentier, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.

V. Calvez, R. Tubiana, C. Katlama, 2010, The Journal of antimicrobial chemotherapy.

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

V. Calvez, R. Tubiana, C. Katlama, 2011, AIDS.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France

V. Calvez, C. Charpentier, J. Izopet, 2019, The Journal of antimicrobial chemotherapy.

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Philippe Flandre, Vincent Calvez, Christine Katlama, 2007, Antimicrobial Agents and Chemotherapy.

Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.

H. Agut, C. Katlama, D. Boutolleau, 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure

V. Calvez, C. Delaugerre, C. Katlama, 2004, Journal of medical virology.

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017

V. Calvez, P. Bellecave, D. Descamps, 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

V. Calvez, C. Katlama, L. Schneider, 2009, AIDS.

Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients

V. Calvez, C. Delaugerre, C. Katlama, 2004, Journal of medical virology.

Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load.

V. Calvez, C. Charpentier, D. Descamps, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

V. Calvez, C. Charpentier, C. Katlama, 2012, The Journal of antimicrobial chemotherapy.

Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.

V. Calvez, R. Tubiana, C. Katlama, 2004, Journal of acquired immune deficiency syndromes.

Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers

V. Calvez, J. Pawlotsky, D. Boutolleau, 2021, Clinical Infectious Diseases.

Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers

V. Calvez, J. Pawlotsky, D. Boutolleau, 2021, bioRxiv.

International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase

V. Calvez, A. Zolopa, Jonathan Taylor, 2010, Antimicrobial Agents and Chemotherapy.

Comparison of Tests and Procedures to Build Clinically Relevant Genotypic Scores: Application to the Jaguar Study

V. Calvez, J. Molina, P. Flandre, 2005, Antiviral therapy.

High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area

V. Calvez, R. Tubiana, C. Katlama, 2022, Journal of Infection.

Impact of HIV-1 Reverse Transcriptase Polymorphism at Codons 211 and 228 on Virological Response to Didanosine

V. Calvez, J. Molina, P. Flandre, 2005, Antiviral therapy.

Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

V. Calvez, C. Delaugerre, C. Katlama, 2004, Antimicrobial Agents and Chemotherapy.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007 – 12: impact on susceptibility to ﬁrst-line strategies

C. Rouzioux, P. Frange, Laurent Tran, 2015 .

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.

V. Calvez, R. Tubiana, C. Katlama, 2008, The Journal of antimicrobial chemotherapy.

More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapy.

V. Calvez, R. Tubiana, C. Katlama, 2022, The Journal of antimicrobial chemotherapy.

Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.

V. Calvez, H. Traoré, S. Fourati, 2013, The Journal of antimicrobial chemotherapy.

Risk factors for raltegravir resistance development in clinical practice.

V. Calvez, C. Katlama, T. Pattery, 2012, The Journal of antimicrobial chemotherapy.

Are Confirmatory Assays Reliable for HIV-1/HIV-2 Infection Differentiation? A Multicenter Study

A. Gautheret-Dejean, Jonathan Bocobza, F. Damond, 2023, Journal of clinical microbiology.

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen

V. Calvez, C. Charpentier, P. André, 2018, The Journal of antimicrobial chemotherapy.

Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals

V. Calvez, C. Katlama, V. Simon, 2010, AIDS.

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

V. Calvez, C. Katlama, O. Delelis, 2008, Antimicrobial Agents and Chemotherapy.

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

V. Calvez, R. Tubiana, C. Katlama, 2011, AIDS.